PF-08046054 by Pfizer for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Wildfire smoke linked to over 52,000 premature deaths in California, study reveals

Research shows wildfire PM2.5 exposure caused over 52,000 premature deaths in California from 2008 to 2018, with significant economic impacts.

June 11, 2024

Genetic risk scores in life insurance underwriting fuel discrimination fears

The integration of genetic risk information, specifically polygenic scores, in life insurance underwriting raises ethical, legal, and social concerns about genetic discrimination, necessitating clear policies

April 2, 2024

Scientists successfully unfroze rat organs and transplanted them — a ‘historic’ step that could someday transform transplant medicine

The rat kidney was peculiarly beautiful — an edgeless viscera about the size of a quarter, gemstone-like and gleaming as if encased in pure glass.

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.